In Vitro Characterization of Five Humanized OKT3 Effector Function Variant Antibodies
Top Cited Papers
- 1 February 2000
- journal article
- Published by Elsevier in Cellular Immunology
- Vol. 200 (1), 16-26
- https://doi.org/10.1006/cimm.2000.1617
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- A NON-ACTIVATING “HUMANIZED” ANTI-CD3 MONOCLONAL ANTIBODY RETAINS IMMUNOSUPPRESSIVE PROPERTIES IN VIVOTransplantation, 1994
- OKT3E, AN ANTI-CD3 ANTIBODY THAT DOES NOT ELICIT SIDE EFFECTS OR ANTIIDIOTYPE RESPONSES IN CHIMPANZEESTransplantation, 1991
- OKT3 F(ABʼ)2 FRAGMENTS—RETENTION OF THE IMMUNOSUPPRESSIVE PROPERTIES OF WHOLE ANTIBODY WITH MARKED REDUCTION IN T CELL ACTIVATION AND LYMPHOKINE RELEASETransplantation, 1991
- OKT3 first-dose reaction: Association with T cell subsets and cytokine releaseKidney International, 1991
- [6] Efficient site-directed mutagenesis using uracil-containing DNAMethods in Enzymology, 1991
- IN VIVO CELL ACTIVATION FOLLOWING OKT3 ADMINISTRATIONTransplantation, 1990
- Characterization of Two Fc Receptors for Mouse Immunoglobulins on Human Monocytes and Cell LinesScandinavian Journal of Immunology, 1987
- Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies.The Journal of Experimental Medicine, 1987
- A Randomized Clinical Trial of OKT3 Monoclonal Antibody for Acute Rejection of Cadaveric Renal TransplantsNew England Journal of Medicine, 1985
- Human in vivo antigenic modulation induced by the anti‐T cell OKT3 monoclonal antibodyEuropean Journal of Immunology, 1982